Select the option that best describes what you are looking for
Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.
Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.
Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.
Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.
Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.
Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.
Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.
Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.
Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.
Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.
Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.
Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.
Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.
Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.
Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.
Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.
Certified CRO services with NanoString GeoMx Digital Spatial Profiling.
De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.
Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.
Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.
Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.
Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.
Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.
Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.
Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.
Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.
We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.
We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.
Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.
Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.
Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.
Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.
Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.
Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.
Phosphorylation is a common type of post translational modifications (PTM), with more than 30% of proteins in cells phosphorylated. It is one of the most fundamental, prevalent, and important mechanisms to regulate and control protein activity and function, and is involved in various physiological and pathological processes, regulating cellular activities such as proliferation, development, differentiation, and apoptosis.
Phosphorylation on different sites on the same peptide can lead to phosphopeptide isomers co-elution on chromatography. These co-eluted phosphopeptide isomers cannot be separated on conventional LC-MS/MS platforms. According to available statistics, at least 26% of phosphopeptides have isomers, 50% of which cannot be effectively differentiated on chromatography, making it difficult to identify phosphorylation sites.
Immobilized metal affinity chromatography (IMAC) strategy: using proprietary targeted antibodies to enrich phosphopeptides, to reduce sample complexity
Additional ion mobility separation enables more reliable and deeper coverage for phosphorylation
Strict dual quality control to remove low confident data: false discovery rate (FDR, 1%); false localization rate (FLR, 0.75)
Upgraded bioinformatic analysis available: kinase prediction, signaling analysis, and data mining
4D technology brings a dramatic increase in detection depth and sensitivity.
>10,000 phosphorylation sites (localization probability > 0.75) were identified with high confidence in various cell tissues, 50% higher than the traditional method.
4D phosphoproteomics resolves the issue of isomerization in PTM through ion mobility separation, which ensures more reliable identification of PTMs.
As shown in the figure, the elution time and mass-to-charge ratio of many phosphorylated peptide isomers are identical, but the structural differences of the phosphorylation locations can be effectively detected by ion mobility.
The separation of both ion mobility and HPLC can maximize the identification and differentiation of these co-eluted modified peptide signals.
Publication
Mouse Stromal Cells Confound Proteomic Characterization and Quantification of Xenograft Models
Poster
Systematic Evaluation of Label-Free Protein Quantification Pipelines (DDA vs DIA)
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2023-12-28
2022-12-08
site_page
Proteomics